
Opinion|Videos|February 10, 2025
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
4
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
5





































































